IGF1R and lung carcinoma: Thus, Src appears to exert mutant KRAS-driven events as its downstream effector, and considering our previous finding demonstrating the involvement of IGF1R activation in the development of lung cancer [37], co-targeting IGF1R and Src may halt the progression of mutant KRAS-driven lung tumor development.